CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

Defines coverage criteria for measurement of serum drug levels and anti-drug antibodies for biologic therapies, primarily addressing inflammatory bowel disease (IBD) versus non-IBD inflammatory conditions for BlueCross BlueShield of Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyImmunopharmacologic Monitoring of Therapeutic Serum Antibodies

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionFor IBD patients, submit requests for drug and/or antibody concentration testing for anti‑TNF, vedolizumab, or ustekinumab at the covered frequency (once every 2 weeks).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

IBD: every 2 wksCovered frequency for drug/antibody concentration testing

Non-IBD: not coveredCoverage stance for non-IBD inflammatory conditions

10 drugsDrugs listed in coverage/reimbursement

9 codesProcedure codes referenced

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

inv-01: Covered — IBD

Coverage determination based on indication:

Covered for IBD: For individuals with inflammatory bowel disease (IBD), drug and/or antibody concentration testing once every two weeks for anti-tumor necrosis factor (anti-TNF) therapies, vedolizumab therapy, or ustekinumab therapy MEETS COVERAGE CRITERIA.testing frequency: once every 2 weeks

applies specifically to IBD indications

inv-02: Not covered — non-IBD inflammatory conditions

Not covered for non-IBD conditions: For individuals with conditions other than IBD (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti-TNF therapies DOES NOT MEET COVERAGE CRITERIA.

explicit exclusion for non-IBD inflammatory conditions

inv-03: Not covered — specified drugs outside covered indication

Not covered — other uses/drugs: Measurement of the serum drug levels and/or measurement of the antibodies to the drugs DOES NOT MEET COVERAGE CRITERIA for any of the following drugs (alone or as a combination test): adalimumab; certolizumab; etanercept; golimumab; infliximab; infliximab-dyyb; infliximab-abda; rituximab; ustekinumab; vedolizumab, except as covered above for IBD.

lists specific drugs not covered outside IBD context

Testing for serum drug concentrations and anti‑drug antibodies is covered only for members with inflammatory bowel disease (IBD). For IBD, measurement of drug and/or antibody concentrations for anti‑TNF therapies, vedolizumab, or ustekinumab is considered to meet coverage criteria when performed once every two weeks. For conditions other than IBD (for example, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis), drug and/or antibody concentration testing for anti‑TNF therapies does not meet coverage criteria and is not covered.

Measurement of serum drug levels and/or antibodies for the specific agents listed in the reimbursement section — including adalimumab, certolizumab, etanercept, golimumab, infliximab (and biosimilars), rituximab, ustekinumab, and vedolizumab — does not meet coverage criteria when used outside the IBD indication described above.

Measurement of serum drug levels and/or anti‑drug antibodies is considered not medically necessary (does not meet coverage criteria) for requests that do not meet the IBD-specific coverage condition. Specifically, testing for members with non‑IBD inflammatory conditions (e.g., spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, psoriasis) is not covered. In addition, measurement of drug levels and/or antibodies for the listed drugs is not covered when performed for indications other than IBD.

Provider Actions and Billing Guidance

Billing Rule

Procedure codes for therapeutic drug monitoring

Procedure codes for therapeutic drug monitoring should be used when submitting reimbursement requests. Include applicable CPT/HCPCS codes on claims and ensure documentation supports testing for IBD when claiming coverage.

Applicable CPT/HCPCS codes: 80145 (Adalimumab), 80230 (Infliximab), 80280 (Vedolizumab), 80299 (Quantitation of therapeutic drug, not elsewhere specified), 82397 (Chemiluminescent assay), 84999 (Unlisted chemistry procedure), 0514U (ad-alimumab immunoassay — Procise ADL™)

Step Therapy

Step therapy not defined

This policy does not establish or require a step therapy sequence. Coverage distinctions are made by indication (for example, testing for IBD versus non-IBD indications). Providers should not interpret this policy as defining step-therapy requirements.

Step therapy: Not defined by this policy; coverage is indication-specific (IBD vs non-IBD)

Documentation Required

Regulatory and laboratory test validation

If there is a conflict between this policy and any applicable governmental coverage determination (e.g., LCDs, NCDs, or state Medicaid policies), the government policy takes precedence. Verify Medicare and Medicaid coverage rules prior to billing.

Medicare LCD/NCD and state Medicaid policies override this policy when applicable
Medicare coverage lookup: https://www.cms.gov/medicarecoverage-database/search.aspx

Denial Risk

Non-IBD testing denial risk

Requests for therapeutic drug and/or antibody concentration testing for indications other than inflammatory bowel disease (IBD) may be denied, as testing for non-IBD conditions does not meet coverage criteria in this policy.

Denial risk: Drug/antibody concentration testing for conditions such as spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis is NOT covered
Covered indication: Testing once every two weeks for anti-TNF, vedolizumab, or ustekinumab therapies for individuals with IBD

Background

Anti‑drug antibodies are immune responses to biologic therapies that can reduce therapeutic efficacy and increase the risk of adverse effects. Therapeutic drug monitoring (measurement of circulating drug concentrations and anti‑drug antibodies) is used to evaluate and manage loss of response to biologic agents; the policy recognizes this rationale and limits coverage primarily to the IBD population where evidence and guideline discussion support its clinical utility.

Because evidence supporting routine monitoring outside IBD is lacking, the policy restricts coverage: TDM is permitted for anti‑TNF agents, vedolizumab, and ustekinumab in IBD at the specified interval, but similar testing for non‑IBD inflammatory conditions is not supported by the available literature and therefore does not meet coverage criteria.

Definitions

Anti-drug antibodies — definition

DefinitionAntibodies developed by a patient’s immune system against administered biologic therapies that can reduce drug efficacy and promote adverse effects.

Clinical relevanceAssociated with loss of response to biologic therapies and potential for adverse reactions, prompting consideration of testing when managing treatment failure.

Common targets/examplesAnti-drug antibodies reported against TNF inhibitors and other biologics such as infliximab, adalimumab, etanercept, and golimumab.

Therapeutic drug monitoring (TDM) — definition

DefinitionMeasurement of circulating drug concentrations and anti-drug antibody levels to assess and manage loss of response to biologic therapies.

PurposeUsed to guide clinical decisions about continuing, stopping, or switching biologic therapy when therapeutic failure is suspected.

Typical contextMost evidence and guideline discussion support use in inflammatory bowel disease; proposed for other inflammatory conditions but coverage varies.

OpenPayer

Immunopharmacologic Monitoring of Therapeutic Serum Antibodies

Coverage Criteria

Coding and Procedure Codes

Provider Actions and Billing Guidance

Background

Definitions

80145	Adalimumab
80230	Infliximab
80280	Vedolizumab
80299	Quantitation of therapeutic drug, not elsewhere specified
82397	Chemiluminescent assay
84999	Unlisted chemistry procedure
0514U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum (ProCise ADL)
0515U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum (ProCise IFXT)